Workflow
SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
SAGESage Therapeutics(SAGE) ZACKS·2024-10-30 14:40

Sage Therapeutics, Inc. (SAGE) reported a loss of 1.53pershareforthethirdquarterof2024,widerthantheZacksConsensusEstimateofalossof1.53 per share for the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 1.52. The company had reported a loss of 2.81pershare(excludingtherestructuringexpenses)intheyear−agoquarter.Revenuesinthethirdquartertotaled2.81 per share (excluding the restructuring expenses) in the year-ago quarter. Revenues in the third quarter totaled 11.8 million, significantly up from $2.7 million reported in the year-ago period. The upside can be attributed to sales of new depression drug Zurzuvae (zuranolone), which is marketed in partnership wi ...